Dr. Imam demonstrated that a selective and bioavailable c-Abl tyrosine kinase inhibitor can protect against MPTP toxicity as determined by neurochemistry and stereology. While the mechanism of protection is unknown, it appears the compound may reduce parkin solubility as a result of c-Abl inhibition. Given the enthusiasm for the data, Dr. Imam will work to develop this target (and potential therapeutic) further.
Imam SZ et al, Novel Regulation of Parkin Function through c-Abl-Mediated Tyrosine Phosphorylation: Implications for Parkinson's Disease, J Neurosci. 2011 Jan 5;31(1):157-163. PMID: 21209200